NEFL and myeloid sarcoma: Particularly neurofilament light chain (NfL) appears to accurately reflect acute axonal damage associated with inflammation but also chronic neuronal damage and has been developed into a validated biomarker in MS with high potential to become a clinically useful biomarker [22,29,30].